patent exclusivity

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...

By Michelle Vitko,Research Analyst Recently, I wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio....

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...

As the expiration of Pfizer's Lipitor exclusivity draws closer, many in the pharmaceutical industry are trying to decipher what the final distribution of statin market share will be. Two factors are contributing to lingering uncertainty, however, making the market...

Key Finding #4 from our Counter-Generics and Biosimilar Threats research: Short-term strategies are still the most popular, but line-extension tactics gaining favor. Over the past three years, short-term strategies, including litigation and defensive pricing,...

Every few years, we conduct a study to gauge the state of counter-generics planning. As we gear up for another study, we took a look back at some of our last key findings. Timing is a critical part of the puzzle, and it's one that frustrated many respondents....

Cutting Edge Information will present its recommendations for developing a successful generics-defense strategy next week. The interactive conference will be based on key findings from "Countering Generic and Biosimilar Threats" study. Based on the company's...

Our analysts synthesized five key findings from the full breadth and depth of our Counter-Generics research. These findings are signposts to help you improve your understanding of other organizations’ approaches to generics competition. While these points are...

Teva Pharmaceuticals Industries has begun recruiting patients with rheumatoid arthritis to participate in clinical trials for the testing of their biosimilar, TL011 (the generic copy of Roche's second best-selling drug Rituxan). This may be the first-ever U.S....

Half of pharmaceutical companies deploy special task forces to plan for drugs' eventual patent expirations. Early results from Cutting Edge Information's ongoing survey, "Counter-Generics Tactics and Biosimilars," show that 50% of surveyed companies create a dedicated...